Log in
Enquire now
YourChoice Therapeutics

YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

OverviewStructured DataIssuesContributors

Contents

yourchoicetx.com
ychoicetx.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Biology
Biology
Technology
Technology
Engineering
Engineering
Biomedical engineering
Biomedical engineering
Fertility
Fertility
Healthcare
Healthcare
Therapeutics
Therapeutics
...
Location
Berkeley, California
Berkeley, California
San Francisco
San Francisco
Lafayette, California
Lafayette, California
B2X
B2B
B2B
CEO
Akash Bakshi
Akash Bakshi
Founder
‌
Polina Lishko
0
Akash Bakshi
Akash Bakshi
0
Nadja Mannowetz
Nadja Mannowetz
‌
Nadja Mannowetz
0
AngelList URL
angel.co/company/yo...herapeutics
Pitchbook URL
pitchbook.com/profiles...266138-92
Accelerator
Y Combinator
Y Combinator
0
Accelerator Batch
‌
Y Combinator W19 Batch
0
Number of Employees (Ranges)
1 – 100
Investors
Olive Tree Capital
Olive Tree Capital
0
Future Ventures
Future Ventures
‌
Erik Peterson (entrepreneur)
Kingsley Advani
Kingsley Advani
Y Combinator
Y Combinator
0
Mehta Ventures
Mehta Ventures
Cleo Capital
Cleo Capital
Civilization Ventures
Civilization Ventures
0
...
DUNS Number
081060870
Founded Date
2018
0
Total Funding Amount (USD)
16,750,000
Latest Funding Round Date
July 20, 2022
Latest Funding Type
Series A
Series A
Wellfound ID
yourchoice-therapeutics
Country
United States
United States

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
15,000,000
Y Combinator URL
ycombinator.com/compani...apeutics0

YourChoice Therapeutics is a biotechnology company that was one of the 2018 CITRIS Foundry Startups founded by Akash Bakshi, Nadja Mannowetz, and Polina Lishko.

One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

Funding
Seed

On January 1, 2019 YourChoice Therapeutics completed a seed funding round with $550,000 in funding from Y Combinator.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Regulation of the sperm calcium channel CatSper by endogenous steroids and plant triterpenoids

Pnas

https://www.pnas.org/content/114/22/5743

Web

YourChoice Therapeutics is developing unisex, non-hormonal birth control

Kate Clark

https://techcrunch.com/2019/03/14/yourchoice-therapeutics-is-developing-unisex-non-hormonal-birth-control/

Web

References

Find more companies like YourChoice Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.